Jing Chun Ng1, Yik Weng Yew2,3. 1. Lee Kong Chian School of Medicine, Singapore, 11 Mandalay Road, Singapore, 308232, Singapore. 2. Lee Kong Chian School of Medicine, Singapore, 11 Mandalay Road, Singapore, 308232, Singapore. ywyew@nsc.com.sg. 3. National Skin Centre, Singapore, 1 Mandalay Road, Singapore, 308205, Singapore. ywyew@nsc.com.sg.
Abstract
BACKGROUND: Previous studies have shown that serum 25-hydroxyvitamin D (25(OH)D) may be associated with atopic dermatitis (AD), and that vitamin D (VD) supplementation may decrease AD severity. OBJECTIVE: The aim of this study was to investigate the association between serum 25(OH)D level and AD, and the effect of VD supplementation on AD severity, while providing stratified analyses based on latitude and region. METHODS: A systematic review was performed on all published studies in MEDLINE, Embase, and Cochrane Library databases that analyzed effects of serum 25(OH)D and VD supplementation on AD. RESULTS: This systematic review and meta-analysis includes 20 studies with 1882 cases of AD. We found significantly lower 25(OH)D levels in AD patients compared with healthy controls (HC) (p < 0.001), significantly lower 25(OH)D levels in severe AD compared with both mild and moderate AD (p < 0.001), and VD supplementation improved AD symptoms (p < 0.001). LIMITATIONS: Factors like seasonal and environmental changes, sunlight exposure, and cultural practices may confound the relationship between serum 25(OH)D and AD severity. There are limited randomized controlled trials that assess this association. CONCLUSION: Overall, lower serum 25(OH)D is associated with more severe AD, and VD supplementation may help lower AD severity. Further research is needed to confirm the presence and direction of causality of the relationship between VD and AD pathogenesis.
BACKGROUND: Previous studies have shown that serum 25-hydroxyvitamin D (25(OH)D) may be associated with atopic dermatitis (AD), and that vitamin D (VD) supplementation may decrease AD severity. OBJECTIVE: The aim of this study was to investigate the association between serum 25(OH)D level and AD, and the effect of VD supplementation on AD severity, while providing stratified analyses based on latitude and region. METHODS: A systematic review was performed on all published studies in MEDLINE, Embase, and Cochrane Library databases that analyzed effects of serum 25(OH)D and VD supplementation on AD. RESULTS: This systematic review and meta-analysis includes 20 studies with 1882 cases of AD. We found significantly lower 25(OH)D levels in AD patients compared with healthy controls (HC) (p < 0.001), significantly lower 25(OH)D levels in severe AD compared with both mild and moderate AD (p < 0.001), and VD supplementation improved AD symptoms (p < 0.001). LIMITATIONS: Factors like seasonal and environmental changes, sunlight exposure, and cultural practices may confound the relationship between serum 25(OH)D and AD severity. There are limited randomized controlled trials that assess this association. CONCLUSION: Overall, lower serum 25(OH)D is associated with more severe AD, and VD supplementation may help lower AD severity. Further research is needed to confirm the presence and direction of causality of the relationship between VD and AD pathogenesis.
Authors: Caroline Y Kuo; John Chase; Maria Garcia Lloret; E Richard Stiehm; Theodore Moore; Maria J Matas Aguilera; Juan Lopez Siles; Joseph A Church Journal: J Allergy Clin Immunol Date: 2013-02-26 Impact factor: 10.793
Authors: Donald Lei; Muhammad Yousaf; Sherief R Janmohamed; Paras P Vakharia; Rishi Chopra; Rajeev Chavda; Sylvie Gabriel; Ryan Sacotte; Kevin R Patel; Vivek Singam; Supriya Immaneni; Robert Kantor; Derek Y Hsu; Jonathan I Silverberg Journal: Ann Allergy Asthma Immunol Date: 2019-12-09 Impact factor: 6.347